LIQUIDIA CORPORATION - COMMON STOCK

Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

18 Apr 2022 16:05:20 By Nasdaq GlobeNewswire

Liquidia Announces Pricing of Public Offering of Common Stock

12 Apr 2022 21:38:07 By Nasdaq GlobeNewswire

Liquidia Announces Proposed Offering of Common Stock

12 Apr 2022 16:17:43 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2022 16:30:52 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update

17 Mar 2022 06:30:57 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022

10 Mar 2022 07:00:37 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million

07 Jan 2022 09:02:51 By Nasdaq GlobeNewswire

Liquidia Corporation Announces Chief Executive Officer Transition

03 Jan 2022 16:52:06 By Nasdaq GlobeNewswire

Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation

29 Dec 2021 06:45:00 By Nasdaq GlobeNewswire

Liquidia to Participate in the Jefferies London Healthcare Conference

11 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

08 Nov 2021 05:45:00 By Nasdaq GlobeNewswire

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update

03 Nov 2021 16:56:12 By Nasdaq GlobeNewswire

Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

08 Oct 2021 17:23:01 By Nasdaq GlobeNewswire

Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

10 Sep 2021 08:29:01 By Nasdaq GlobeNewswire

FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility

18 Aug 2021 16:15:00 By Nasdaq GlobeNewswire

U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent

12 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update

10 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021

03 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

02 Jun 2021 07:00:00 By Nasdaq GlobeNewswire